健择联合顺铂治疗晚期非小细胞肺癌近期疗效观察

Gemcitabine Plus Cisplatin Combination In The Treatment of Advanced Non-small Cell Lung Cancer

目的：观察健择（GEM，吉西他滨）与顺铂（DDP）联合化疗方案治疗晚期非小细胞肺癌（NSCLC）的临床疗效及毒副反应。方法：18例病人均为不能手术的Ⅲ、Ⅳ期非小细胞肺癌患者。健择1000mg／m^2于30～60min内静滴，顺铂第1～3d40mg／m^2静滴，21d为1个周期，治疗2～3个周期。结果：总有效率为44．4％（均为部分缓解）。主要毒副反应为Ⅱ～Ⅲ度骨髓抑制及恶心呕吐。骨髓抑制主要表现为血色素、白细胞及血小板的降低，但没有严重的Ⅲ、Ⅳ度损害。无明显的肝肾功能的损害。无1例因毒性反应而延期化疗者。结论：健择联合顺铂化疗方案治疗晚期非小细胞肺癌有较好疗效，耐受性较好。

Objective： To observe the clinical effect and toxicity of the combination of chemotherapy with Gemcitabine and Cisplatin in the treatment of advanced non - small cell lung cancer. Methods ：All of the eighteen patients were non - small cell lung cancer（ NSCLC） in stages Ⅲ and Ⅳ which had no chance to have operation. Gemcitabine was given on the day 1 and 8 at a dose of 1000mg/m^2 and Cisplatin on the day 1 - 3 at a dose of 40mg/m^2. The chemotherapy was repeated every 21 days and a period of treatment included 2 - 3 therapy. Resuits：The overall effective rate was 44.4 %. The main toxicity were marrow inhibition in grade Ⅱ～Ⅲ, nausea and vomiting. The marrow inhibition included hemoglobin, leukocyte and thrombocyte decrease. But there were no obviously damage in grade Ⅲ～Ⅳ and there were no liver and kidney damage. No one was delayed in ehernotherapy because of the toxicity. Conclusions： The regimen of Gemcitabine and Cisplatin is effective and well tolerated in the treatment of advanced non - small cell lung cancer.